Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models

Current state of immunotherapy for glioblastoma

(2018) Michael Lim et al.   Nature Reviews Clinical Oncology

Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma

(2017) Alan T. Yeo et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Immunotherapy for Brain Tumors

(2017) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series

(2017) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

The immune contexture in cancer prognosis and treatment

(2017) Wolf H. Fridman et al.   Nature Reviews Clinical Oncology

Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma

(2017) Tatenda Mahlokozera et al.   NEURO-ONCOLOGY

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma

(2017) Abhishek D. Garg et al.   OncoImmunology

Trial watch: Immune checkpoint blockers for cancer therapy

(2017) Claire Vanpouille-Box et al.   OncoImmunology

Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses

(2016) Leandro M. Colli et al.   CANCER RESEARCH

Emerging Opportunities and Challenges in Cancer Immunotherapy

(2016) T. L. Whiteside et al.   CLINICAL CANCER RESEARCH

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

Clonal evolution of glioblastoma under therapy

(2016) Jiguang Wang et al.   NATURE GENETICS

Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach

(2016) T. M. Johanns et al.   Cancer Immunology Research

Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?

(2016) Valérie Dutoit et al.   Frontiers in Oncology

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity

(2015) M. Derouazi et al.   CANCER RESEARCH

The CD40/CD40L axis in glioma progression and therapy

(2015) Paul R. Walker et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

(2015) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Immune Checkpoint Blockade in Patients With Melanoma Metastatic to the Brain

(2015) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

(2015) D. A. Reardon et al.   Cancer Immunology Research

Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma

(2014) S Han et al.   BRITISH JOURNAL OF CANCER

Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells

(2014) Akemi Kosaka et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Immunocompetent murine models for the study of glioblastoma immunotherapy

(2014) Taemin Oh et al.   Journal of Translational Medicine

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class

(2013) W. C. Rutledge et al.   CLINICAL CANCER RESEARCH

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients

(2010) T. Di Tomaso et al.   CLINICAL CANCER RESEARCH

Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing

(2008) Jason T. Huse et al.   BRAIN PATHOLOGY

Epitope Landscape in Breast and Colorectal Cancer

(2008) N. H. Segal et al.   CANCER RESEARCH